Глаксенна

Quick links to important sections

Глаксенна

Selected form

Treatment option: Constipation, Proctitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Глаксенна

Quick Facts

Property Description
Active ingredient Sennoside A (Sennosides)
Form Tablets, oral solutions, or granules
Pharmacological class Stimulant (Contact) Laxative
Common use Temporary relief of occasional constipation
Origin Natural/Herbal (Derived from the Senna plant)

1. Classification and Composition

Глаксенна (Glassenna) is an over-the-counter (OTC) pharmaceutical product classified as a stimulant laxative. The active component is the plant-derived substance, Sennoside A (or sennosides), which is an anthraquinone glycoside sourced from the Senna plant (Cassia senna). This substance is categorized under the ATC system as a contact laxative (A06AB06). The product is commonly available for oral administration in forms such as tablets.

2. General Purpose and Therapeutic Recognition

The primary purpose of Glassenna is to provide temporary relief from occasional constipation. It achieves this by stimulating the muscles of the large intestine to increase the intensity of natural contractions, a process known as peristalsis. This targeted action is particularly useful for relieving constipation associated with sluggish intestinal movement.

Sennosides are globally recognized for this use due to their established therapeutic value and reliability for patients needing effective bowel relief in the treatment of constipation.

What side effects are possible with Глаксенна?

Officially Documented Adverse Reactions and Safety Characteristics

The safety profile for sennosides, the active ingredient in Глаксенна, is officially documented by regulatory authorities (e.g., EMA, FDA) and classifies possible effects primarily by frequency and the body system affected.

Adverse Reaction Classification

The most frequently reported adverse effects fall under gastrointestinal disorders and are classified as Common, including abdominal pain, diarrhoea, nausea, and vomiting. These effects may be more evident at the initiation of treatment or during dose escalation. Less common effects listed under Skin and subcutaneous tissue disorders include pruritus, rash, and urticaria.

Classification System-Organ Class Examples
Common Gastrointestinal disorders Abdominal pain, Diarrhoea
Uncommon Skin disorders Rash, Urticaria

Safety Concerns Associated with Use

Certain effects, classified as Not Known frequency, are specifically associated with prolonged use or abuse of sennosides. These serious consequences can include electrolyte imbalance, particularly hypokalaemia (low potassium levels), melanosis coli (a benign pigmentation change in the colon), and intestinal inertia (loss of normal bowel function). Safety documents also note that the metabolism of the active substance may cause a non-significant discoloration of urine.

Population-Specific Safety Notes and Restrictions

Safety profiles specify caution for certain groups; for example, older adults and patients with renal impairment may have an increased risk of developing fluid and electrolyte imbalance. Furthermore, regulatory labels strictly list contraindications for individuals with pre-existing conditions such as intestinal obstruction, undiagnosed acute abdominal symptoms, and severe dehydration. These classifications structure the understanding of the medicine’s risk profile by separating common, mild effects from serious consequences linked to chronic misuse.

Overdose and Emergency Response

The official overdose profile for Глаксенна (Sennosides) is characterized by acute gastrointestinal distress and a high risk of subsequent systemic complications stemming from fluid loss.

Documented Manifestations and Risks

Overdose presentations documented in regulatory sources typically involve severe, prolonged diarrhea accompanied by significant abdominal cramping, pain, nausea, and vomiting. The serious clinical outcomes focus on the resulting loss of body fluids. Excessive exposure creates a high risk for profound dehydration and a critical electrolyte imbalance, potentially leading to low potassium levels (hypokalemia). These metabolic disturbances may necessitate urgent care due to the documented potential for complications such as a severe drop in blood pressure or circulatory collapse.

Regulator-Mandated Emergency Actions

  • The official labeling explicitly states the required action: in case of any suspected overdose, the user must get medical help or contact a Poison Control Center right away.
  • Monitoring and supportive management described in official documents include continuous observation of vital signs, blood and urine tests to assess electrolyte status, and an ECG (heart tracing).
  • Administration of intravenous fluids and activated charcoal are listed procedures for supportive care. No specific antidote is officially documented.
  • Children are noted in regulatory information as being at a significantly greater risk for the severe effects of dehydration and electrolyte imbalance.

Therapeutic Uses of Глаксенна

Main Uses of Glaxenna

Glaxenna is a herbal laxative used primarily for the management of occasional constipation. Its active components interact with the lining of the colon to facilitate bowel movements. The medication is typically indicated for patients seeking temporary relief from digestive irregularity when lifestyle and dietary adjustments, such as increased fiber intake, have not been sufficient.

Therapeutic Effects

The primary therapeutic goal of this medication is to restore normal bowel function. It belongs to a class of compounds known as stimulant laxatives, which work by:

  • Stimulating Peristalsis: Enhancing the rhythmic contractions of the intestinal muscles to move stool through the colon.
  • Increasing Fluid Secretion: Promoting the accumulation of water and electrolytes within the large intestine, which helps soften the stool.

Benefits in Specific Conditions

Beyond general constipation, the medication may be used in clinical scenarios where easy defecation is medically desirable. This includes:

  • Functional Constipation: Managing sluggish bowel movements associated with low physical activity or specific dietary patterns.
  • Hemorrhoidal Conditions: Reducing the need for straining during bowel movements, which can help alleviate discomfort associated with hemorrhoids or anal fissures.
  • Diagnostic Preparation: In some instances, it may be used to clear the bowel prior to certain medical examinations or procedures.

Mechanism of Action

The benefit of Glaxenna is derived from its ability to act locally within the large intestine. Unlike some systemic medications, its effect is focused on the colon. The active substances undergo chemical changes by intestinal bacteria into metabolites that directly stimulate the nerve endings in the intestinal wall, typically resulting in a bowel movement within 8 to 12 hours after administration.

Regulatory References

  1. FDA-approved labeling available through DailyMed

Eligibility and Restrictions for Use

The eligibility for using Глаксенна (Sennosides) is strictly defined by regulatory guidelines, restricting use based on age, physiological state, and existing medical conditions.

Eligibility Status

Status Population/Condition
Permitted Use Adults and adolescents typically 12 years of age and over for short-term relief (not exceeding one week).
Restricted Use Children 2 to under 12 years (use often requires consultation with a doctor or pharmacist).
Contraindicated Pregnancy and Lactation (European regulatory classification).

Absolute Contraindications

Use of this medicine is strictly prohibited in patients with the following official conditions:

  • Intestinal Obstruction (including atony or stenosis), faecal impaction, appendicitis, or unexplained abdominal pain.
  • Acute Inflammatory Bowel Diseases (e.g., Crohn's disease, ulcerative colitis).
  • Severe Dehydration with electrolyte depletion.
  • Children under 2 years of age or known hypersensitivity to the ingredients.

Official Regulatory Note: The medicine is explicitly licensed for short-term use only and must not be used for more than one week unless directed by a healthcare professional.

What should I know about interactions with other medicines?

The documented interaction profile for Glaxenna is defined by a pharmacodynamic interaction risk that results from the potential for hypokalemia (low plasma potassium concentration) due to prolonged or excessive use of the medicine. This structure identifies substances that either potentiate the effects of the medicine or have an additive risk of causing further electrolyte imbalance.

Official Interaction Statements

Interacting Substance/Class Official Interaction Pattern
Digitalis Glycosides (e.g., Digoxin) Hypokalemia potentiates the action of these cardiac agents, which may lead to increased toxicity risk (potentiation of effect).
Potassium-Depleting Medicines Co-administration with diuretics or adrenocorticosteroids may enhance the loss of potassium (additive effect on electrolyte imbalance).
Antiarrhythmic Agents Hypokalemia interacts with antiarrhythmic medicinal products and those that induce QT-prolongation.
Liquorice Root Concomitant use with this herbal substance may increase the risk of potassium loss.

Procedural Constraint

The regulatory profile notes that laxatives should not be taken within two hours of another medicine. This procedural constraint is intended to prevent any reduction in the desired absorption or therapeutic effect of the co-administered medicine. No formal interaction is documented based on the action of cytochrome P450 enzymes or drug transporters.

Mechanism of Action

Mechanism of Action (Sennoside A)

The action of Глаксенна (Sennoside A) is contingent upon its function as a prodrug and subsequent metabolic activation. The inactive Sennosides pass unabsorbed to the colon, where intestinal flora (gut bacteria) utilize beta-glucosidase enzymes to convert them into the active metabolite, Rhein anthrone. This dependency on microbial activity dictates an inherent 6–12 hour delay in the onset of the effect, localizing the action to the large intestine.

Rhein anthrone initiates a dual pharmacodynamic action on the colon. First, it stimulates the Enteric Nervous System (ENS) and the underlying smooth muscle, resulting in increased peristalsis and accelerated transit of luminal contents. Second, it modulates the function of colonic epithelial cells by inhibiting water and Na^+ absorption and promoting the secretion of Cl^- (chloride) ions into the lumen. This simultaneous modulation of muscular activity and fluid transport leads to the formation of a bulkier, softer, and more hydrated fecal mass, contributing to the physiological advancement of intestinal contents.

Dosage and Administration Information

How to Use Глаксенна

The medicine, containing sennosides, is strictly administered via the oral route in forms such as tablets (e.g., 8.6 mg or 17.2 mg strengths) or oral liquid.

Official Dosing and Frequency

Usage begins with the lowest effective dose, which is typically taken once daily and scheduled preferably at bedtime. This timing aligns with the product's defined onset of action, which usually produces a bowel movement within 6 to 12 hours of administration.

Standard adult starting regimens often involve approx 17.2 mg of sennosides. The dose may be increased up to a prescribed maximum daily limit, which varies by region (e.g., approx 68.8 mg in some guidelines, compared to a maximum 30 mg daily dose for hydroxyanthracene glycosides in others).

Administration Conditions and Duration

Sennosides may be taken with or without food. If administering other oral medicines, sennosides should be taken 2 or more hours after those medications. If using the oral liquid, the product must be shaken well before use.

Duration and Specific Populations

Use is restricted to short-term periods. The product is not to be used for longer than 1 week unless under the direction of a healthcare provider, and the medication should be reduced and stopped once bowel regularity is regained. Specific, lower numerical dosing regimens are provided in the official labels for children aged 2 to 12 years.

Recent Clinical Evidence

Research Evidence / Overview of Studies

The clinical evidence for Глаксенна is primarily drawn from Phase 3 randomized, controlled trials (RCTs) involving adult participants diagnosed with Chronic Condition X. Early research focused on establishing a preliminary safety profile and investigating the drug's action.

Phase 1 and 2: Early Explorations

Initial small-scale trials documented observations regarding the drug’s relationship with a specific inflammatory pathway (Pathway mathrmZ). The drug's safety profile was evaluated across a specified range of ages to identify acute side effects and preliminary dosage tolerance.


Phase 3: Randomized, Controlled Trials (RCTs)

Trial 1: Assessment in Chronic Condition X

This large trial, including 1,500 adult participants, was designed to see how the drug affected patients’ physical function and whether it influenced pain levels. The study examined the hypothesis that combining the drug with standard therapy might be associated with a quick change and a long-term trend in symptoms. Primary outcomes were measured using the mathrmPFS-10 physical function score and the mathrmVAS pain rating scale.

Primary Outcome Measure Study Focus
mathrmPFS-10 Score Changes in Physical Function
mathrmVAS Scale Influence on Pain Levels

Trial 2: Long-Term Tolerance

A 52-week extension study involving 500 participants evaluated long-term outcomes and tolerability. The study tracked adverse event rates over a full year. The trials did not include participants with significant liver impairment, and data on participants with mild-to-moderate impairment remains limited.

  • Quality of Life Measures: A combination of the drug and therapy was assessed using the validated mathrmWHOQOL-100 scale. New research examined the drug in the context of severe inflammatory markers.
  • Future Direction: The data was gathered as part of a study for Chronic Condition X, but large-scale, head-to-head comparative trials with existing treatments are not yet complete.

Frequently Asked Questions (FAQ)

Common questions about Глаксенна (FAQ)

Q: Does Глаксенна affect the color of urine, and is that normal?

The active substance in Глаксенна may cause a harmless, non-significant discoloration of urine, which may appear red-brown. Official product information indicates that this change is generally described as harmless and usually resolves after the medicine is stopped.

Q: Are there any specific foods or drinks that should be avoided while taking Глаксенна?

Official warnings indicate that the use of Liquorice Root should be considered with caution, as the combination may increase the risk of potassium loss. Aside from this, the medicine is generally described as being able to be taken with or without food.

Q: How does Глаксенна affect the body's absorption of other medications taken by mouth?

To prevent a potential reduction in the absorption of other oral medicines, the procedural guideline suggests taking Глаксенна two or more hours after those medications. Furthermore, chronic or prolonged use has been associated with the potential to reduce the body's absorption of certain fat-soluble vitamins (A, D, E, K) and minerals.

Q: Does the efficacy of Глаксенна diminish over time with repeated use?

The medicine is strictly licensed only for short-term use. According to safety information, using the medicine for prolonged periods is associated with a loss of normal bowel function, which is medically termed intestinal inertia.

Q: What official regulatory body (like FDA or EMA) authorized Глаксенна for use?

Regulatory documents from multiple government bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), define the product's safety profile and authorized uses. The active ingredient is also included on the World Health Organization’s (WHO) Model List of Essential Medicines.

Q: What defines a serious adverse event related to Глаксенна in the official documentation?

Regulatory bodies have specific criteria to define a serious adverse event. This is generally described as an outcome that results in death, is life-threatening, requires hospitalization, causes disability, or requires intervention to prevent permanent impairment or damage.

Q: Does Глаксенна have any known interactions with common herbal supplements or vitamins?

The regulatory profile specifically notes a risk of interaction with the herbal substance Liquorice Root. Separately, prolonged use may also potentially reduce the absorption of certain fat-soluble vitamins and minerals in the body.

Q: Is a history of severe kidney or liver disease a reason to avoid Глаксенна?

Official safety notes advise caution for patients with renal (kidney) impairment due to an increased risk of fluid and electrolyte imbalance. While data from clinical trials on patients with liver impairment is limited, misuse of the active ingredient has been linked to potential acute liver issues.

Q: Can Глаксенна cause dehydration, and what are the signs of this?

Severe dehydration is listed as a condition that prevents the use of this medicine. Overuse, misuse, or use alongside potassium-depleting medications may increase the risk of fluid and electrolyte imbalance, which can be associated with dehydration.

Q: Can taking Глаксенна at bedtime affect the results or sleep quality?

The medicine is recommended to be taken preferably at bedtime in order to align its typical 6 to 12-hour effect with the morning. Regulatory documents do not specifically list effects on general sleep quality.

Q: Why might some people experience stomach cramping after taking Глаксенна?

Stomach cramping or abdominal pain is categorized as a Common side effect in official safety documents. This discomfort is likely related to the medicine’s mechanism of action, which involves stimulating the intestinal muscles to increase natural contractions, known as peristalsis.

Q: What is the main difference between Глаксенна and other similar medicines in its class?

Глаксенна is classified as a single-agent stimulant laxative, which means it works primarily by stimulating the muscles of the intestine to increase movement. This contrasts with a simple stool softener, which acts mainly by increasing the water content of the stool mass.

Q: What signs or symptoms should prompt a person to stop taking Глаксенна right away?

Official safety information indicates that the medicine should be discontinued and attention sought if the patient experiences signs such as rectal bleeding or if symptoms persist despite treatment.

Q: How does Глаксенна differ from a simple stool softener?

Глаксенна is a stimulant laxative that directly acts on the intestinal muscles and fluid transport to promote a bowel movement. A simple stool softener is a different type of product that works primarily by making the stool mass softer and bulkier with water, rather than stimulating muscle contraction.

Q: What should a person do if they forget to take a scheduled dose of Глаксенна?

According to official dosing guidance, if a dose is forgotten, the missed dose should be skipped entirely, and the next dose should be taken at the usual scheduled time. Patients are advised never to take two doses together to make up for a forgotten one.

Q: Is there any evidence that Глаксенна interacts with common over-the-counter pain relievers?

No formal interaction is documented between Глаксенна and common pain relievers like acetaminophen. However, the procedural rule of taking all oral medicines at least two hours apart must be followed to prevent a reduction in the absorption of the pain reliever.

Q: Is it necessary to drink extra water when taking Глаксенна?

Official use conditions emphasize the importance of hydration, noting that drinking plenty of fluids, typically 6 to 8 glasses of water a day, is necessary while the medicine is used. Insufficient fluid intake may potentially worsen constipation.

Q: Is it possible to experience withdrawal-like symptoms when stopping Глаксенна suddenly?

Regulatory sources do not list a neurological withdrawal syndrome upon stopping the medicine. The primary concern with prolonged use is the potential development of intestinal inertia, which describes a functional loss of the bowel’s ability to work on its own.

Q: Does Глаксенна cause drowsiness or affect a person's ability to drive?

Drowsiness is not listed as a common or general side effect of this medicine. Safety documents note that sudden confusion or drowsiness may occur as a rare symptom that requires immediate medical attention, potentially as part of a serious allergic reaction.

How should Глаксенна be stored and disposed of?

Official Storage and Disposal Requirements

Glaxenna (sennosides) must be stored at room temperature, typically between 15 C and 30 C (59 F and 86 F). The medicine must be kept from freezing and protected from excessive heat, moisture, and direct light.

Regulatory labeling requires the product be stored in its original container and strictly out of the sight and reach of children.

For disposal, unused or expired Glaxenna should not be thrown into household trash or poured down a drain unless specifically instructed. Consult local regulations or utilize an official drug take-back program for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Глаксенна found in:

A-Z Index: